InnoCare Pharma (2595) said its board has formally resolved to exercise its share repurchase mandate and plans to buy back H shares in the open market from time to time, according to Ming Pao.
The maximum repurchase amount is capped at HK$350 million, and the buyback period will run until the repurchase mandate expires.
STOCKS | InnoCare Pharma to Buy Back Up to HK$350 Million of H Shares
2026-06-29 05:49:26
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
